VIB-RUG Department of Molecular Biomedical Research

Molecular ImmunoBiotechnology Unit









Immunotherapy with Bispecific Antibodies

A first effect of treatment with Bispecific Antibodies will of course be the direct killing of the target cell by redirecting the cellular toxicity of the effector cell. This is a passive effect: this action will cease once the reagent is removed from the body, and it involves effector cells that have no specificity for the target. 
Although this already a desirable effect which many therapies see as an endpoint, it is possible that by using Bispecific Antibodies, we can achieve more. A correctly stimulated effector cell will release signal molecules towards other immune cells, notifying them of a dangerous situation. The normally immunosuppressive tumor environment can be made pro-inflammatory by these released signals. If antigen presenting cells start presenting also tumor antigens, a specific immune reaction could follow. Since the immune system continues to react after removal of the triggering reagent, this is called an active effect. In fact, we can compare it with vaccination, but here we bring the adjuvant to the antigen.

[Antibodies] [Immunotherapy] [BsAb] [Tribody]




Research projects


After eight

Check out 

links to:

MABs on the market
Antibody Companies
Immune Therapy Companies
Custom protein expression and purification
Biotech in Flanders
Flanders Universities
Flanders Biotech Policy


2002 Webmaster